pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

972 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT783Endpoints585BioPharma Dive224onclive165BioSpace59Fierce Biotech57raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • STAT+: Trump administration releases rules for new Medicaid work requirements
    States are racing to implement the new requirements by the start of next year.
    STAT · 1mo ago↗ source
  • STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
    Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.
    STAT · 1mo ago↗ source
  • STAT+: Global coalition to fast-track three vaccines targeting Ebola outbreak with $62 million in funding
    With no licensed vaccines available to protect against the Ebola virus currently spreading in the Congo, efforts are underway to fast-track development of at least three vaccines.
← prev
page 20 of 39
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
STAT · 1mo ago
↗ source
  • STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
    Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
    STAT · 1mo ago↗ source
  • STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
    Here is some of what you may have missed from the world's largest cancer research meeting.
    STAT · 1mo ago↗ source
  • STAT+: At the world’s largest cancer research meeting, data briefly took a backseat to grief
    At the world's largest cancer research meeting, new data were plentiful. But this year, there was also a focus on grief.
    STAT · 1mo ago↗ source
  • As FDA misses deadline on electric shock ban, disability advocates speak out
    The FDA has missed a self-imposed deadline to ban the use of electrical shock devices in people with intellectual disabilities.
    STAT · 1mo ago↗ source
  • STAT+: Medicare’s mum on GLP-1s, and Massachusetts sues United
    We've been asking Medicare for weeks about the cost of giving seniors $50 obesity drugs.
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
    Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
    STAT · 1mo ago↗ source
  • Opinion: What should hospitals do when patients demand unvaccinated donor blood?
    “You have to understand a person's belief if you want to address it,” Deva Sharma says on the “First Opinion Podcast” about requests for unvaccinated donor blood.
    STAT · 1mo ago↗ source
  • STAT+: A turning point for pancreatic cancer patients
    Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • CDC says containing the spread of Ebola is top priority
    The Trump administration disregards infectious disease playbook, CEPI offers vaccine funding, and other health news from Morning Rounds
    STAT · 1mo ago↗ source
  • STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
    The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
    STAT · 1mo ago↗ source
  • Opinion: The military’s medical corps has a serious recruitment problem
    Congress must incentivize more physicians (and their employers) to join the military medical corps, writes the former attending physician to Congress.
    STAT · 1mo ago↗ source
  • Opinion: Medical schools diversified. So where are all the diverse doctors?
    Why are residency programs disciplining and dismissing trainees in a system funded to train them?
    STAT · 1mo ago↗ source
  • STAT+: Executives reveal tech initiatives at Summa Health, eight months after General Catalyst acquisition
    Two years after General Catalyst said it was buying Ohio safety-net hospital Summa Health, executives shed light on how the “transformation” is going.
    STAT · 1mo ago↗ source
  • STAT+: Medicare still won’t say how much covering obesity drugs will cost
    Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing how much this will cost taxpayers.
    STAT · 1mo ago↗ source
  • The hidden history of BPC-157, a favorite MAHA peptide
    A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.
    STAT · 1mo ago↗ source
  • STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes
    The arbitration process has protected patients but generated financial windfalls for some clinicians.
    STAT · 1mo ago↗ source
  • STAT+: A standing ovation for RevMed, and caution for Akeso
    ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
    STAT · 1mo ago↗ source
  • Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
    Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
    STAT · 1mo ago↗ source
  • STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
    Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
    STAT · 1mo ago↗ source
  • STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
    A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
    STAT · 1mo ago↗ source
  • STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
    By doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
    STAT · 1mo ago↗ source
  • STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
    ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
    STAT · 1mo ago↗ source